Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

Published:2017-08-22 Issue:1 Volume:110 Page:87-96
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Suciu Stefan¹,Eggermont Alexander M M²,Lorigan Paul³,Kirkwood John M⁴,Markovic Svetomir N⁵,Garbe Claus⁶,Cameron David⁷,Kotapati Srividya⁸,Chen Tai-Tsang⁸,Wheatley Keith⁹,Ives Natalie¹⁰,de Schaetzen Gaetan¹,Efendi Achmad¹¹,Buyse Marc¹²

Affiliation:

1. European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

2. Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

3. The Christie NHS Foundation Trust, Manchester, UK

4. University of Pittsburgh Cancer Institute and School of Medicine, Pittsburgh, PA

5. Mayo Clinic Rochester, Rochester, MN

6. University of Tubingen, Tubingen, Germany

7. University of Edinburgh, Western General Hospital, Edinburgh, UK

8. Bristol-Myers Squibb, Wallingford, CT

9. Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK

10. Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK

11. Universitas Brawijaya, Malang, Indonesia

12. IDDI, Louvain-la-Neuve, Belgium

Funder

Bristol-Myers Squibb

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/1/87/24367604/djx133.pdf

Reference53 articles.

1. The Evaluation of Surrogate Endpoints

2. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer;Leo;J Clin Oncol.,2003

3. Detecting an overall survival benefit that is derived from progression-free survival;Broglio;J Natl Cancer Inst.,2009

4. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis;Buyse;Lancet.,2000

5. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer;Burzykowski;J Clin Oncol.,2008

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions;Cancers;2024-07-29

3. Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma;Melanoma Research;2024-05-27

4. Systemic Therapy for Melanoma: ASCO Guideline Update;Journal of Clinical Oncology;2023-10-20

5. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial;Nature Medicine;2023-10-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3